Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer

Roland Hubaux, Kelsie L. Thu, Emily A. Vucic, Larissa A. Pikor, Sonia H Y Kung, Victor D. Martinez, Mitra Mosslemi, Daiana D. Becker-Santos, Adi F. Gazdar, Stephen Lam, Wan L. Lam

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Microtubule affinity-regulating kinases (MARKs) are involved in several cellular functions but few studies have correlated MARK kinase expression with cancer, and none have explored their role in lung cancer. In this study, we identified MARK2 as frequently disrupted by DNA hypomethylation and copy gain, resulting in concordant overexpression in independent lung tumor cohorts and we demonstrate a role for MARK2 in lung tumor biology. Manipulation of MARK2 in lung cell lines revealed its involvement in cell viability and anchorage-independent growth. Analyses of both manipulated cell lines and clinical tumor specimens identified a potential role for MARK2 in cell cycle activation and DNA repair. Associations between MARK2 and the E2F, Myc/Max and NF-κB pathways were identified by luciferase assays and in-depth assessment of the NF-κB pathway suggests a negative association between MARK2 expression and NF-κB due to activation of non-canonical NF-κB signaling. Finally, we show that high MARK2 expression levels correlate with resistance to cisplatin, a standard first line chemotherapy for lung cancer. Collectively, our work supports a role for MARK2 in promoting malignant phenotypes of lung cancer and potentially modulating response to the DNA damaging chemotherapeutic, cisplatin. What's new? Microtubule affinity-regulating kinases (MARKs) have been implicated in multiple cellular processes, including intracellular transport, cell polarity, and cell migration. Yet, few studies have correlated MARK kinase expression with cancer, and none have explored their role in lung cancer. Here, the authors describe for the first time highly frequent DNA and RNA-level disruption of MARK2 in clinical non-small cell lung cancer (NSCLC) cases. They provide evidence supporting a novel role for MARK2 in promoting malignant phenotypes of lung cancer, and in potentially modulating response to the DNA damaging chemotherapeutic agent cisplatin.

Original languageEnglish (US)
Pages (from-to)2072-2082
Number of pages11
JournalInternational Journal of Cancer
Volume137
Issue number9
DOIs
StatePublished - Nov 1 2015

Fingerprint

Non-Small Cell Lung Carcinoma
Microtubules
Cisplatin
DNA Damage
Phosphotransferases
Lung Neoplasms
DNA
Lung
Neoplasms
Phenotype
Cell Polarity
Tumor Cell Line
Luciferases
DNA Repair
Cell Movement
Cell Survival
Cell Cycle
RNA
Drug Therapy
Cell Line

Keywords

  • cisplatin resistance
  • DNA damage repair
  • lung cancer
  • MARK2
  • NFκB

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer. / Hubaux, Roland; Thu, Kelsie L.; Vucic, Emily A.; Pikor, Larissa A.; Kung, Sonia H Y; Martinez, Victor D.; Mosslemi, Mitra; Becker-Santos, Daiana D.; Gazdar, Adi F.; Lam, Stephen; Lam, Wan L.

In: International Journal of Cancer, Vol. 137, No. 9, 01.11.2015, p. 2072-2082.

Research output: Contribution to journalArticle

Hubaux, R, Thu, KL, Vucic, EA, Pikor, LA, Kung, SHY, Martinez, VD, Mosslemi, M, Becker-Santos, DD, Gazdar, AF, Lam, S & Lam, WL 2015, 'Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer', International Journal of Cancer, vol. 137, no. 9, pp. 2072-2082. https://doi.org/10.1002/ijc.29577
Hubaux, Roland ; Thu, Kelsie L. ; Vucic, Emily A. ; Pikor, Larissa A. ; Kung, Sonia H Y ; Martinez, Victor D. ; Mosslemi, Mitra ; Becker-Santos, Daiana D. ; Gazdar, Adi F. ; Lam, Stephen ; Lam, Wan L. / Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer. In: International Journal of Cancer. 2015 ; Vol. 137, No. 9. pp. 2072-2082.
@article{931cd73e523c4e8791ec9691e3511b91,
title = "Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer",
abstract = "Microtubule affinity-regulating kinases (MARKs) are involved in several cellular functions but few studies have correlated MARK kinase expression with cancer, and none have explored their role in lung cancer. In this study, we identified MARK2 as frequently disrupted by DNA hypomethylation and copy gain, resulting in concordant overexpression in independent lung tumor cohorts and we demonstrate a role for MARK2 in lung tumor biology. Manipulation of MARK2 in lung cell lines revealed its involvement in cell viability and anchorage-independent growth. Analyses of both manipulated cell lines and clinical tumor specimens identified a potential role for MARK2 in cell cycle activation and DNA repair. Associations between MARK2 and the E2F, Myc/Max and NF-κB pathways were identified by luciferase assays and in-depth assessment of the NF-κB pathway suggests a negative association between MARK2 expression and NF-κB due to activation of non-canonical NF-κB signaling. Finally, we show that high MARK2 expression levels correlate with resistance to cisplatin, a standard first line chemotherapy for lung cancer. Collectively, our work supports a role for MARK2 in promoting malignant phenotypes of lung cancer and potentially modulating response to the DNA damaging chemotherapeutic, cisplatin. What's new? Microtubule affinity-regulating kinases (MARKs) have been implicated in multiple cellular processes, including intracellular transport, cell polarity, and cell migration. Yet, few studies have correlated MARK kinase expression with cancer, and none have explored their role in lung cancer. Here, the authors describe for the first time highly frequent DNA and RNA-level disruption of MARK2 in clinical non-small cell lung cancer (NSCLC) cases. They provide evidence supporting a novel role for MARK2 in promoting malignant phenotypes of lung cancer, and in potentially modulating response to the DNA damaging chemotherapeutic agent cisplatin.",
keywords = "cisplatin resistance, DNA damage repair, lung cancer, MARK2, NFκB",
author = "Roland Hubaux and Thu, {Kelsie L.} and Vucic, {Emily A.} and Pikor, {Larissa A.} and Kung, {Sonia H Y} and Martinez, {Victor D.} and Mitra Mosslemi and Becker-Santos, {Daiana D.} and Gazdar, {Adi F.} and Stephen Lam and Lam, {Wan L.}",
year = "2015",
month = "11",
day = "1",
doi = "10.1002/ijc.29577",
language = "English (US)",
volume = "137",
pages = "2072--2082",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - Microtubule affinity-regulating kinase 2 is associated with DNA damage response and cisplatin resistance in non-small cell lung cancer

AU - Hubaux, Roland

AU - Thu, Kelsie L.

AU - Vucic, Emily A.

AU - Pikor, Larissa A.

AU - Kung, Sonia H Y

AU - Martinez, Victor D.

AU - Mosslemi, Mitra

AU - Becker-Santos, Daiana D.

AU - Gazdar, Adi F.

AU - Lam, Stephen

AU - Lam, Wan L.

PY - 2015/11/1

Y1 - 2015/11/1

N2 - Microtubule affinity-regulating kinases (MARKs) are involved in several cellular functions but few studies have correlated MARK kinase expression with cancer, and none have explored their role in lung cancer. In this study, we identified MARK2 as frequently disrupted by DNA hypomethylation and copy gain, resulting in concordant overexpression in independent lung tumor cohorts and we demonstrate a role for MARK2 in lung tumor biology. Manipulation of MARK2 in lung cell lines revealed its involvement in cell viability and anchorage-independent growth. Analyses of both manipulated cell lines and clinical tumor specimens identified a potential role for MARK2 in cell cycle activation and DNA repair. Associations between MARK2 and the E2F, Myc/Max and NF-κB pathways were identified by luciferase assays and in-depth assessment of the NF-κB pathway suggests a negative association between MARK2 expression and NF-κB due to activation of non-canonical NF-κB signaling. Finally, we show that high MARK2 expression levels correlate with resistance to cisplatin, a standard first line chemotherapy for lung cancer. Collectively, our work supports a role for MARK2 in promoting malignant phenotypes of lung cancer and potentially modulating response to the DNA damaging chemotherapeutic, cisplatin. What's new? Microtubule affinity-regulating kinases (MARKs) have been implicated in multiple cellular processes, including intracellular transport, cell polarity, and cell migration. Yet, few studies have correlated MARK kinase expression with cancer, and none have explored their role in lung cancer. Here, the authors describe for the first time highly frequent DNA and RNA-level disruption of MARK2 in clinical non-small cell lung cancer (NSCLC) cases. They provide evidence supporting a novel role for MARK2 in promoting malignant phenotypes of lung cancer, and in potentially modulating response to the DNA damaging chemotherapeutic agent cisplatin.

AB - Microtubule affinity-regulating kinases (MARKs) are involved in several cellular functions but few studies have correlated MARK kinase expression with cancer, and none have explored their role in lung cancer. In this study, we identified MARK2 as frequently disrupted by DNA hypomethylation and copy gain, resulting in concordant overexpression in independent lung tumor cohorts and we demonstrate a role for MARK2 in lung tumor biology. Manipulation of MARK2 in lung cell lines revealed its involvement in cell viability and anchorage-independent growth. Analyses of both manipulated cell lines and clinical tumor specimens identified a potential role for MARK2 in cell cycle activation and DNA repair. Associations between MARK2 and the E2F, Myc/Max and NF-κB pathways were identified by luciferase assays and in-depth assessment of the NF-κB pathway suggests a negative association between MARK2 expression and NF-κB due to activation of non-canonical NF-κB signaling. Finally, we show that high MARK2 expression levels correlate with resistance to cisplatin, a standard first line chemotherapy for lung cancer. Collectively, our work supports a role for MARK2 in promoting malignant phenotypes of lung cancer and potentially modulating response to the DNA damaging chemotherapeutic, cisplatin. What's new? Microtubule affinity-regulating kinases (MARKs) have been implicated in multiple cellular processes, including intracellular transport, cell polarity, and cell migration. Yet, few studies have correlated MARK kinase expression with cancer, and none have explored their role in lung cancer. Here, the authors describe for the first time highly frequent DNA and RNA-level disruption of MARK2 in clinical non-small cell lung cancer (NSCLC) cases. They provide evidence supporting a novel role for MARK2 in promoting malignant phenotypes of lung cancer, and in potentially modulating response to the DNA damaging chemotherapeutic agent cisplatin.

KW - cisplatin resistance

KW - DNA damage repair

KW - lung cancer

KW - MARK2

KW - NFκB

UR - http://www.scopus.com/inward/record.url?scp=84939588821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939588821&partnerID=8YFLogxK

U2 - 10.1002/ijc.29577

DO - 10.1002/ijc.29577

M3 - Article

C2 - 25907283

AN - SCOPUS:84939588821

VL - 137

SP - 2072

EP - 2082

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 9

ER -